Alexion is accelerating the development of asfotase alfa , a first-in-class targeted enzyme replacement therapy in Phase 2 clinical trials for Hypophosphatasia (HPP). HPP is an ultra-rare, genetic and life-threatening metabolic disease with no effective treatment options. Read more
Alexion has been named #2 in Forbes’ annual ranking of The World’s Most Innovative Companies. At Alexion we are committed to transforming the lives of patients with severe and life-threatening ultra-rare disorders and we are honored to receive this recognition for our work.
Alexion joins the European Organization for Rare Diseases (EURORDIS), the National Organization for Rare Disorders (NORD) and patient organizations worldwide in celebrating Rare Disease Day 2013, a global effort to focus attention on rare diseases, their profound impact on patients, and the need for improved diagnosis and treatment. Read more
Since Alexion was founded in 1992, the Company has grown to a global organization with over 1,100 employees working in more than 30 countries. In 2012, Alexion has lead development programs underway with five highly innovative therapeutics, including Soliris® (eculizumab), which are being investigated across eight severe and ultra-rare disorders beyond the currently approved indications of PNH and aHUS.
Soliris® (eculizumab) is now approved by the U.S. Food and Drug Administration (FDA) and by the
European Commission (EC) for the treatment of adult and pediatric patients with atypical hemolytic
uremic syndrome (aHUS). The effectiveness of Soliris in aHUS is based on the effects on thrombotic
microangiopathy (TMA) and renal function. Prospective clinical trials in additional patients are ongoing
to confirm the benefit of Soliris in patients with aHUS. Soliris is not indicated for the treatment of
patients with Shiga toxin E coli-related hemolytic uremic syndrome (STEC-HUS).
Click here to read the FDA approval press release, and click here to read the EC approval press release.
Click here for U.S. Prescribing Information. Click here for Important Safety information.
Alexion was honored by the National Organization for Rare Disorders (NORD) with a “Partners in Progress” Corporate Award for bringing to market the first and only treatment for patients with atypical hemolytic uremic syndrome (aHUS).
The award was given at the NORD gala in Washington, D.C. on May 15th, an annual event that honors government officials, patient advocates, medical researchers, and companies that have made a difference in the lives of patients with rare diseases.
Alexion is expanding its OneSource™ Treatment Support Program to U.S. patients with atypical hemolytic uremic syndrome (aHUS)
now that the FDA has approved Soliris for this use. Since 2007, OneSource has provided personalized, ongoing support for
patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare, life-threatening blood disorder. Patients and families in the United States affected by
aHUS can call 1-888-SOLIRIS to speak with an Alexion Nurse Case Manager, who can help answer questions about the OneSource program,
discuss funding options for Soliris, provide education on disease and drug, and provide ongoing treatment support.
When Victor Estevez developed PNH, the upbeat, energetic event worker who was busy planning a future with his wife-to-be was suddenly facing long hospitalizations, debilitating pain and fatigue, and a sense of isolation from his loved ones. Find out how Victor learned to manage his disease and is once again sharing happy moments with his growing family. Play video.
Members of the aHUS community discuss their experience living with aHUS and the significance of the FDA approval of Soliris as a treatment for this devastating disease.
Soliris® (eculizumab) is the first therapy approved for
the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Visit
the new Soliris site,
, to learn more about Soliris and PNH, read patient stories,
join our patient support program and get updates on the latest research.
Alexion is now hiring for a range of positions, from marketing to research and development and support functions. We’re looking for people who share our passion and commitment to transforming the lives of patients with life-threatening ultra-rare diseases. We invite you to learn more about our company and our culture by meeting our team and reviewing our career opportunities.